Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST BMT CTN 1903

Next Previous
Trial Profile

Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST BMT CTN 1903

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary)
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Primary-Effusion-Lymphoma
  • Focus Therapeutic Use
  • Acronyms Auto -RESIST; BMT CTN 1903

Most Recent Events

  • 25 Mar 2026 Actual primary completion date changed from 20 Aug 2025 to 24 Nov 2025.
  • 25 Mar 2026 Status changed from active, no longer recruiting to completed.
  • 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top